Cagrilintide Peptide for Weight Loss Appetite Control & Metabolic Support Three new #obesity drugshigh dose semaglutide, semaglutide plus cagrilintide, and oral orforglipronmay soon be approved in the US. JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin examine how Recent advances in peptide based therapies for obesity and type 2 diabetes ScienceDirect cagrisema #tirzepatide #cagrilintide #semaglutide #obesity #weightloss #redefine4 Martin Haluzk Anti Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance Circulation: Heart Failure CagriSema vs Tirzepatide: 23% Weight Loss in Phase 3 Trial